← Back to Clinical Trials
Recruiting NCT07039292

NCT07039292 Clinical Alternatives for Reducing Harm Using E-cigarettes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07039292
Status Recruiting
Phase
Sponsor Medical University of South Carolina
Condition Smoking
Study Type INTERVENTIONAL
Enrollment 208 participants
Start Date 2025-08-25
Primary Completion 2029-05-31

Trial Parameters

Condition Smoking
Sponsor Medical University of South Carolina
Study Type INTERVENTIONAL
Phase N/A
Enrollment 208
Sex ALL
Min Age 21 Years
Max Age N/A
Start Date 2025-08-25
Completion 2029-05-31
Interventions
Harm Reduction (E-cigarette switching)Standard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

For patients in cancer care, quitting smoking is critical, but a significant portion of patients in cancer care refuse all components of tobacco treatment, even when offered free of charge. The proposed clinical trial will assess one harm reduction intervention, switching completely from cigarettes to e-cigarettes, among oncology outpatients who smoke and refuse traditional tobacco treatment. This study is a type 1 hybrid effectiveness-implementation trial among oncology outpatients at an NCI-designated cancer center who smoke and refuse all components of tobacco treatment (N=208).

Eligibility Criteria

Inclusion Criteria: * age 21+, * identified as smoking in their medical record and self-report of current smoking within the past 30 days * refused traditional treatment options through the opt-out HCC Tobacco Treatment Program * English speaking; Exclusion Criteria: * currently taking part in any TTP or using cessation medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline, or in another study), * use of e-cigarettes in the past 30 days, * currently imprisoned, * pregnant women.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology